Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom

OBJECTIVE: To estimate the cost-effectiveness of adding a selective phosphodiesterase-4 inhibitor, roflumilast, to a long-acting bronchodilator therapy (LABA) for the treatment of patients with severe-to-very severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis with...

Descripción completa

Detalles Bibliográficos
Autores principales: Samyshkin, Yevgeniy, Kotchie, Robert W., Mörk, Ann-Christin, Briggs, Andrew H., Bateman, Eric D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889819/
https://www.ncbi.nlm.nih.gov/pubmed/23392624
http://dx.doi.org/10.1007/s10198-013-0456-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889819/
https://www.ncbi.nlm.nih.gov/pubmed/23392624
http://dx.doi.org/10.1007/s10198-013-0456-5

Ejemplares similares